Check out your Company Bowl for anonymous work chats.
Grifols continued to deliver strong financial results in 2019, reporting 3.7 billion in revenues for the first nine months of the year. The company delivered solid performance across all its business divisions. Please see full results here: http://glassdoor.com/slink.htm?key=vMHXV
Grifols is proud to celebrate International Plasma Awareness Week. We appreciate the kindness and generosity of plasma donors everywhere for helping to save patients’ lives. To learn more about the importance of plasma donation, visit http://glassdoor.com/slink.htm?key=vMY9T. #plasmaprotein #IPAW2019
Grifols publishes its 2018 CSR report, an in-depth review of the company’s social, environmental and economic achievements. The report highlights Grifols’ firm commitment and pledge of transparency to stakeholders such as donors, patients, medical professionals, employees and society as a whole.
► Grifols continues to expand its plasma donation center network in the US The additional 26 plasma donation centers acquired from Interstate Blood Bank Inc. further solidify Grifols’ global leadership position in plasma collection and plasma-derived therapies. Our 286 centers in the U.S. and Europe provide the plasma we use to meet the growing demand for our medicines to treat chronic, rare and life-threatening diseases.
Grifols plans to attend two major Bay Area networking events this week: BioSpace Biotech Bay on 4/29 and the University of California Alumni fair on 5/2. As a company committed to people, we are always looking for talent that will continue to diversify our team. Click here to learn more about what it means to join the Grifols family: http://glassdoor.com/slink.htm?key=vMvpO
We’ve begun processing the first batch of plasma from survivors of Ebola—the culmination of an agreement with the Republic of Liberia to produce anti-Ebola immunoglobulin in the context of a clinical research program to combat the virus. This innovative initiative has the potential to revolutionize the way in which we respond to epidemics and reaffirms our commitment to head on international public health emergencies wherever they may arise. http://glassdoor.com/slink.htm?key=vQofS
Grifols Diagnostic Solutions featured in the San Francisco Business Times Grifols Diagnostic Solutions was recently featured in a supplement to the SF Business Times! Quoting leadership from the Diagnostic Commercial Division, the article discusses Grifols’ commitment to the Bay Area region, future plans for investment in the Emeryville site and its social impact on the neighboring communities. Click here to read the article: http://glassdoor.com/slink.htm?key=vQOhw
